Conversion of der p 23, a new major house dust mite allergen, into a hypoallergenic vaccine

Journal of Immunology

Volumn 192, Issue 10, 2014, Pages 4867-4875

  Banerjee, Srinita ^a   Weber, Milena ^a   Blatt, Katharina ^a   Swoboda, Ines ^a,b   Focke Tejkl, Margit ^a   Valent, Peter ^a   Valenta, Rudolf ^a   Vrtala, Susanne ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF APPLIED SCIENCES   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; HOUSE DUST ALLERGEN; HOUSE DUST ALLERGEN 23; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; SERINE; UNCLASSIFIED DRUG;

ALLERGENICITY; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG SYNTHESIS; ESCHERICHIA COLI; HOUSE DUST ALLERGY; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION;

ALLERGENS; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; BASOPHILS; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOGLOBULIN E; INTERFERON-GAMMA; INTERLEUKIN-10; MALE; PYROGLYPHIDAE; RABBITS; RECOMBINANT PROTEINS; TH1 CELLS; VACCINES;

EID: 84901257014     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400064     Document Type: Article

References (42)

1. Vrtala, S., H. Huber, and W. R. Thomas. 2014. Recombinant house dust mite allergens. Methods. 66: 67-74.
2. Heinzerling, L., A. J. Frew, C. Bindslev-Jensen, S. Bonini, J. Bousquet, M. Bresciani, K. H. Carlsen, P. van Cauwenberge, U. Darsow, W. J. Fokkens, et al. 2005. Standard skin prick testing and sensitization to inhalant allergens across Europe-a survey from the GALEN network. Allergy 60: 1287-1300.
3. Platts-Mills, T. A., G. Rakes, and P. W. Heymann. 2000. The relevance of allergen exposure to the development of asthma in childhood. J. Allergy Clin. Immunol. 105: S503-S508.
4. Jacquet, A. 2011. The role of the house dust mite-induced innate immunity in development of allergic response. Int. Arch. Allergy Immunol. 155: 95-105.
5. O'Brien, R. M., andW. R. Thomas. 1994. Immune reactivity to Der p I and Der p II in house dust mite sensitive patients attending paediatric and adult allergy clinics. Clin. Exp. Allergy 24: 737-742.
6. Pittner, G., S. Vrtala, W. R. Thomas, M. Weghofer, M. Kundi, F. Horak, D. Kraft, and R. Valenta. 2004. Component-resolved diagnosis of house-dust mite allergy with purified natural and recombinant mite allergens. Clin. Exp. Allergy 34: 597-603.
7. Weghofer, M., W. R. Thomas, M. Kronqvist, A. Mari, A. Purohit, G. Pauli, F. Horak, H. Grölnlund, M. van Hage, R. Valenta, and S. Vrtala. 2008. Variability of IgE reactivity profiles among European mite allergic patients. Eur. J. Clin. Invest. 38: 959-965.
8. Weghofer, M., M. Grote, Y. Resch, A. Casset, M. Kneidinger, J. Kopec, W. R. Thomas, E. Fernández-Caldas, M. Kabesch, R. Ferrara, et al. 2013. Identification of Der p 23, a peritrophin-like protein, as a new major Dermatophagoides pteronyssinus allergen associated with the peritrophic matrix of mite fecal pellets. J. Immunol. 190: 3059-3067.
9. Tovey, E. R., M. D. Chapman, and T. A. Platts-Mills. 1981. Mite faeces are a major source of house dust allergens. Nature 289: 592-593.
10. Casset, A., A. Mari, A. Purohit, Y. Resch, M. Weghofer, R. Ferrara, W. R. Thomas, C. Alessandri, K. W. Chen, F. de Blay, et al. 2012. Varying allergen composition and content affects the in vivo allergenic activity of commercial Dermatophagoides pteronyssinus extracts. Int. Arch. Allergy Immunol. 159: 253-262.
11. Brunetto, B., R. Tinghino, M. C. Braschi, L. Antonicelli, C. Pini, and P. Iacovacci. 2010. Characterization and comparison of commercially available mite extracts for in vivo diagnosis. Allergy 65: 184-190.
12. Walker, S. M., G. B. Pajno, M. T. Lima, D. R. Wilson, and S. R. Durham. 2001. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J. Allergy Clin. Immunol. 107: 87-93.
13. Bousquet, J., and F. B. Michel. 1994. Specific immunotherapy in asthma. Allergy Proc. 15: 329-333.
14. Larché, M. 2011. T cell epitope-based allergy vaccines. Curr. Top. Microbiol. Immunol. 352: 107-119.
15. Cromwell, O., D. Häfner, and A. Nandy. 2011. Recombinant allergens for specific immunotherapy. J. Allergy Clin. Immunol. 127: 865-872.
16. Valenta, R., B. Linhart, I. Swoboda, and V. Niederberger. 2011. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens. Allergy 66: 775-783.
17. Rancitelli, P., A. Hofmann, and A. W. Burks. 2011. Vaccine approaches for food allergy. Curr. Top. Microbiol. Immunol. 352: 55-69.
18. Mascarell, L., A. Zimmer, L. Van Overtvelt, S. Tourdot, and P. Moingeon. 2011. Induction of allergen-specific tolerance via mucosal routes. Curr. Top. Microbiol. Immunol. 352: 85-105.
19. Senti, G., P. Johansen, and T. M. Kundig. 2011. Intralymphatic immunotherapy: from the rationale to human applications. Curr. Top. Microbiol. Immunol. 352: 71-84.
20. Asturias, J. A., I. Ibarrola, M. C. Arilla, C. Vidal, A. Ferrer, P. M. Gamboa, J. E. Viñuela, M. L. Sanz, C. Andreu, and A. Martínez. 2009. Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen-specific immunotherapy. Clin. Exp. Allergy 39: 1088-1098.
21. Chen, K. W., K. Blatt, W. R. Thomas, I. Swoboda, P. Valent, R. Valenta, and S. Vrtala. 2012. Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy. J. Allergy. Clin. Immunol. 130: 435-443.e4.
22. Walgraffe, D., C. Mattéotti, M. El Bakkoury, L. Garcia, C. Marchand, D. Bullens, M. Vandenbranden, and A. Jacquet. 2009. A hypoallergenic variant of Der p 1 as a candidate for mite allergy vaccines. J. Allergy Clin. Immunol. 123: 1150-1156.
23. Neurath, A. R., and S. B. Kent. 1988. The pre-S region of hepadnavirus envelope proteins. Adv. Virus Res. 34: 65-142.
24. Niespodziana, K., M. Focke-Tejkl, B. Linhart, V. Civaj, K. Blatt, P. Valent, M. van Hage, H. Gronlund, and R. Valenta. 2011. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J. Allergy Clin. Immunol. 127: 1562-1570.e6.
25. Marth, K., I. Breyer, M. Focke-Tejkl, K. Blatt, M. H. Shamji, J. Layhadi, A. Gieras, I. Swoboda, D. Zafred, W. Keller, et al. 2013. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype. J. Immunol. 190: 3068-3078.
26. Focke, M., V. Mahler, T. Ball, W. R. Sperr, Y. Majlesi, P. Valent, D. Kraft, and R. Valenta. 2001. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J. 15: 2042-2044.
27. Westritschnig, K., M. Focke, P. Verdino, W. Goessler, W. Keller, A. Twardosz, A. Mari, F. Horak, U. Wiedermann, A. Hartl, et al. 2004. Generation of an allergy vaccine by disruption of the three-dimensional structure of the cross-reactive calcium-binding allergen, Phl p 7. J. Immunol. 172: 5684-5692.
28. Fling, S. P., and D. S. Gregerson. 1986. Peptide and protein molecular weight determination by electrophoresis using a high-molarity tris buffer system without urea. Anal. Biochem. 155: 83-88.
29. Resch, Y., M. Weghofer, S. Seiberler, F. Horak, S. Scheiblhofer, B. Linhart, I. Swoboda, W. R. Thomas, J. Thalhamer, R. Valenta, and S. Vrtala. 2011. Molecular characterization of Der p 10: a diagnostic marker for broad sensitization in house dust mite allergy. Clin. Exp. Allergy 41: 1468-1477.
30. Chen, K. W., G. Fuchs, K. Sonneck, A. Gieras, I. Swoboda, N. Douladiris, B. Linhart, M. Jankovic, T. Pavkov, W. Keller, et al. 2008. Reduction of the in vivo allergenicity of Der p 2, the major house-dust mite allergen, by genetic engineering. Mol. Immunol. 45: 2486-2498.
31. Campana, R., S. Vrtala, B. Maderegger, P. Jertschin, G. Stegfellner, I. Swoboda, M. Focke-Tejkl, K. Blatt, A. Gieras, D. Zafred, et al. 2010. Hypoallergenic derivatives of the major birch pollen allergen Bet v 1 obtained by rational sequence reassembly. J. Allergy Clin. Immunol. 126: 1024-1031, 1031.e1-8.
32. Swoboda, I., A. Bugajska-Schretter, P. Verdino, W. Keller, W. R. Sperr, P. Valent, R. Valenta, and S. Spitzauer. 2002. Recombinant carp parvalbumin, the major cross-reactive fish allergen: a tool for diagnosis and therapy of fish allergy. J. Immunol. 168: 4576-4584.
33. Vrtala, S., M. Fohr, R. Campana, C. Baumgartner, P. Valent, and R. Valenta. 2011. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination. Vaccine 29: 2140-2148.
34. Hauswirth, A. W., S. Natter, M. Ghannadan, Y. Majlesi, G. H. Schernthaner, W. R. Sperr, H. J. Buhring, R. Valenta, and P. Valent. 2002. Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. J. Allergy Clin. Immunol. 110: 102-109.
35. Twaroch, T. E., M. Focke, K. Fleischmann, N. Balic, C. Lupinek, K. Blatt, R. Ferrara, A. Mari, C. Ebner, P. Valent, et al. 2012. Carrier-bound Alt a 1 peptides without allergenic activity for vaccination against Alternaria alternata allergy. Clin. Exp. Allergy 42: 966-975.
36. Twaroch, T. E., M. Focke, V. Civaj, M. Weber, N. Balic, A. Mari, R. Ferrara, S. Quirce, S. Spitzauer, I. Swoboda, and R. Valenta. 2011. Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy. J. Allergy Clin. Immunol. 128: 178-184.e7.
37. Muttil, P., C. Prego, L. Garcia-Contreras, B. Pulliam, J. K. Fallon, C. Wang, A. J. Hickey, and D. Edwards. 2010. Immunization of guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary route. AAPS J. 12: 330-337.
38. Akçakaya, N., A. Hassanzadeh, Y. Camcioglu, and H. Cokugraş. 2000. Local and systemic reactions during immunotherapy with adsorbed extracts of house dust mite in children. Ann. Allergy Asthma Immunol. 85: 317-321.
39. Mellerup, M. T., G. W. Hahn, L. K. Poulsen, and H. Malling. 2000. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin. Exp. Allergy 30: 1423-1429.
40. Focke-Tejkl, M., and R. Valenta. 2012. Safety of engineered allergenspecific immunotherapy vaccines. Curr. Opin. Allergy Clin. Immunol. 12: 555-563.
41. Chen, K. W., M. Focke-Tejkl, K. Blatt, M. Kneidinger, A. Gieras, F. Dall'Antonia, I. Faé , G. Fischer, W. Keller, P. Valent, et al. 2012. Carrierbound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen-induced basophil activation in allergic patients. Allergy 67: 609-621.
42. Rendi-Wagner, P., D. Shouval, B. Genton, Y. Lurie, H. Rumke, G. Boland, A. Cerny, M. Heim, D. Bach, M. Schroeder, and H. Kollaritsch. 2006. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 24: 2781-2789.